Is corona virus infection a risk factor for hematuria in secondary bladder amyloidosis? The first case report

Djafari, Anahita Ansari; Hasanzadeh, Katayoun; Masrour, Homa; Ahadi, Mahsa; Dargahi, Majid; Rahavian, Amirhossein

doi:10.1016/j.eucr.2021.101642

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This protein can promote inflammatory responses through the activation of cytokines and induction of chemotaxis, 10 and is associated with disease severity and poor prognosis. 5 Djafari, et al 11 reported a case in which a 68-year-old female was diagnosed with secondary bladder amyloidosis after developing gross hematuria during hospitalization for COVID-19 infection. In this case, considering that the abdominal pain, diarrhea, and hematochezia manifested after the SARS-CoV-2 reinfection, it is possible that immune and inflammatory responses induced by this reinfection contributed to gastric amyloid deposition.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report

Park

Choi

et al. 2023

Yonsei Med J

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with the overproduction of serum amyloid A protein, resulting in systemic AA amyloidosis. In this report, we describe a case of gastrointestinal (GI) AA amyloidosis following SARS-CoV-2 infection. A 75-year-old male presented to the emergency department with upper abdominal pain 6 weeks post kidney transplantation. He had a history of SARS-CoV-2 infection 4 weeks prior. On day 7 of hospitalization, while receiving conservative management, the patient developed symptoms of cough and fever, leading to a diagnosis of SARS-CoV-2 reinfection. The patient’s abdominal pain persisted, and hematochezia developed on day 30 of hospitalization. Esophagogastroduodenoscopy and colonoscopy revealed multiple ulcers in the stomach and colon, with histologic findings revealing the presence of amyloid A. The patient was managed conservatively and was also given remdesivir for the SARS-CoV-2 infection. His clinical symptoms subsequently improved, and endoscopic findings demonstrated improvement in multiple gastric ulcers. GI amyloidosis may be a subacute complication following SARS-CoV-2 infection in immunocompromised patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report

Park

Choi

et al. 2023

Yonsei Med J

View full text Add to dashboard Cite

show abstract

“…Djafari et al [ 42 ] (see Table 2 ) reported a case of 68-year-old woman with a ten-day history of shortness of breath and fever who tested positive for COVID-19 infection. She had a background of secondary amyloidosis with kidney involvement due to rheumatoid arthritis.…”

Section: Reported Cases Of Covid-19 Infection-induced Amyloidosismentioning

confidence: 99%

COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?

Leung

Floyd

et al. 2023

Vaccines

View full text Add to dashboard Cite

Amyloidosis is a complex disorder characterized by deposited insoluble fibrillar proteins which misfold into β-pleated sheets. The pathogenesis of amyloidosis can vary but can be the result of immune dysregulation that occurs from sustained high inflammatory states, often known as AA amyloidosis. Multi-organ involvement including hepatic, gastrointestinal, renal, cardiac and immunological pathological manifestations has been observed amongst individuals presenting with amyloidosis. The recent global pandemic of severe acute respiratory syndrome coronavirus 2, also referred to as coronavirus 2019 (COVID-19), has been shown to be associated with multiple health complications, many of which are similar to those seen in amyloidosis. Though COVID-19 is recognized primarily as a respiratory disease, it has since been found to have a range of extra-pulmonary manifestations, many of which are observed in patients with amyloidosis. These include features of oxidative stress, chronic inflammation and thrombotic risks. It is well known that viral illnesses have been associated with the triggering of autoimmune conditions of which amyloidosis is no different. Over the recent months, reports of new-onset and relapsed disease following COVID-19 infection and vaccination have been published. Despite this, the exact pathophysiological associations of COVID-19 and amyloidosis remain unclear. We present a scoping review based on our systematic search of available evidence relating to amyloidosis, COVID-19 infection and COVID-19 vaccination, evaluating current perspectives and providing insight into knowledge gaps that still needs to be addressed going forward.

show abstract

Is corona virus infection a risk factor for hematuria in secondary bladder amyloidosis? The first case report

Cited by 2 publications

References 4 publications

Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report

Gastrointestinal AA Amyloidosis following Recurrent SARS-CoV-2 Infection: A Case Report

COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?

Contact Info

Product

Resources

About